

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN AUG 24 2007 ACTION REGARDING A PATENT OR TRADEMARK U.S. PATENT & TRADEMARK OFFICE
---	--

In Compliance with 35 § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
 filed in the U.S. District Court for the District of Maryland on the following ☐ Patents or ☐ Trademarks:

DOCKET NO. AW-02-1135	DATE FILED	U.S. DISTRICT COURT FOR THE DISTRICT OF MARYLAND
PLAINTIFF Medimmune, Inc.		DEFENDANT Centocor, Inc., et al
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,807,715		
2		
3		
4		
5		

In the above—entitled case, the following patent(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT See attached
--

CLERK Felicia C. Cannon	(BY) DEPUTY CLERK 	DATE 8/22/07
----------------------------	-----------------------	-----------------

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MARYLAND

FILED _____ ENTERED _____
LODGED _____ RECEIVED _____
AUG 22 2007

MEDIMMUNE, INC.,

Plaintiff

v.

CENTOCOR, INC., et al.,

Defendants

AT GREENBELT
CLERK U.S. DISTRICT COURT
DISTRICT OF MARYLAND
BY _____ DEPUTY

Civil Action No.: AW-02-CV-1135

...ooOoo...

ORDER


This matter having come before the Court on a Motion for Voluntary Dismissal filed by Plaintiff MedImmune, Inc. ("MedImmune") pursuant to Rule 41(a)(2) of the Federal Rules of Civil Procedure, and this Court having considered the matter and being sufficiently advised, IT IS ORDERED, ADJUDGED AND DECREED THAT:

1. The Court has specific personal jurisdiction over the parties for purposes of this action only.
2. MedImmune's claims against Defendants Centocor, Inc. ("Centocor"), The Trustees of Columbia University in the City of New York ("Columbia") and The Board of Trustees of the Leland Stanford Junior University ("Stanford") (together with Columbia, the "Universities") in the above-captioned action are hereby dismissed with prejudice; and
3. In the event that an infringement action under U.S. Patent No. 5,807,715 (the '715 Patent) is brought against MedImmune or an affiliate of MedImmune with respect to an immunoglobulin that at no time in the past or future was or is licensed under the '715 Patent, MedImmune or its affiliate shall have the right to defend such

action on the basis that such immunoglobulin does not infringe and/or that the '715 Patent is invalid and/or unenforceable, except that MedImmune shall not have the right to assert a defense of invalidity or unenforceability in defense of an infringement action under the '715 patent with respect to any of the immunoglobulins of Exhibit I attached hereto or immunologically functional fragments thereof.

4. Each side is to bear its own costs and attorneys' fees in connection with the above-captioned action.

SO ORDERED this 22nd day of August, 2007 .



HON. ALEXANDER WILLIAMS
United States District Judge

EXHIBIT I

Immunoglobulins against any of the following:

Respiratory Syncytial Virus (RSV) (Except for Numax and Synagis)
Human Metapneumovirus (hMPV)
Staphylococcus epidermis
Staphylococcus aureus
Candida albicans

Interleukin-9 (IL-9)
Interleukin-5 Receptor (IL-5R)
Interleukin-6 (IL-6)
Interferon alpha (IFN α)
Interferon alpha Receptor (IFN α R)
CD19
CD20
CD22
High Mobility Group Box 1 (HMGB1)
YKL40
Acidic Mammalian Chitinase (AMCase)
Chitotriosidase
Inducible co-stimulator (ICOS)
Receptor for Advanced Glycosylation End products (RAGE)
C5a

CD2
EphA2
EphA4
EphB4
Ephrin B2
Anaplastic Lymphoma Kinase (ALK)
 $\alpha_v\beta_3$